TAXUS Libertē Post Approval Study

• ClinicalTrials.gov Identifier: NCT00997503
• Recruitment Status: Completed
• First Posted: October 19, 2009
• Results First Posted: April 13, 2015
• Last Update Posted: August 7, 2015
• Sponsor: Boston Scientific Corporation
• Collaborators: Eli Lilly and Company; Daiichi Sankyo, Inc.
• Information provided by (Responsible Party): Boston Scientific Corporation

Study Description

Brief Summary:

The TAXUS Libertē Post-Approval Study is an FDA-mandated prospective, multi-center study designed to collect real-world safety and clinical outcomes in approximately 4,200 patients receiving one or more TAXUS Liberté Paclitaxel-Eluting Stents and prasugrel as part of a dual antiplatelet therapy (DAPT) drug regimen.

This study will also contribute patient data to an FDA-requested and industry-sponsored research study that will evaluate the optimal duration of dual antiplatelet therapy (DAPT Study).

Condition or disease	Intervention/treatment
Coronary Artery Disease	Device: TAXUS Liberté Paclitaxel-Eluting Coronary Stent; Drug: prasugrel; Drug: placebo; Drug: aspirin

Detailed Description:

The TAXUS Libertē Post-Approval Study is an FDA-mandated prospective, multi-center study designed to collect real-world safety and clinical outcomes in approximately 4,200 patients receiving one or more TAXUS Liberté Paclitaxel-Eluting Stents and prasugrel as part of a dual antiplatelet therapy (DAPT) drug regimen. This is a consecutively-enrolled study with patient follow-up through 3 years post index procedure. This study also will contribute patient data to an FDA-requested and industry-sponsored research study that will evaluate the optimal duration of dual antiplatelet therapy (DAPT Study). To facilitate this patient data contribution, patients will be assigned to patient groups based upon their co-morbidities and stented lesions identified post index procedure.

All enrolled patients who have been treated with the TAXUS Liberté Stent will be assigned to 12 months of open-label prasugrel treatment and aspirin. Upon completion of the open-label period, patients who are clear of events at 12 months post index procedure will be randomized 1:1 to either a placebo or prasugrel for an additional 18 months of treatment. All patients will receive aspirin therapy throughout the course of the study.

Study Design

• Study Type: Observational
• Actual Enrollment: 4199 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: TAXUS Libertē Post Approval Study: A U.S. Post-Approval Study of the TAXUS® Liberté® Paclitaxel-Eluting Coronary Stent System
• Study Start Date: December 2009
• Actual Primary Completion Date: March 2013
• Actual Study Completion Date: July 2015

Groups and Cohorts

Intervention Details:

• Device: TAXUS Liberté Paclitaxel-Eluting Coronary Stent
  The TAXUS Liberté Paclitaxel-Eluting Coronary Stent System is a device/drug combination product comprised of two regulated components: a device (Liberté Coronary Stent System) and a drug product (a formulation of paclitaxel contained in a polymer coating).The polymer coating serves as a carrier system to provide uniform and controlled biphasic release of the drug into the vessel wall once the stent is deployed.
• Drug: prasugrel
  10mg or 5mg, oral, once daily as maintenance dose through 30-months following index procedure
  Other Name: Effient
• Drug: placebo
  Oral placebo to match both 10mg and 5mg prasugrel tablets.
• Drug: aspirin

  Oral, as prescribed by physician through end of study.

  .

Outcome Measures

Primary Outcome Measures :

1. Cardiac Death or Myocardial Infarction [ Time Frame: 12 months ]
   Cardiac death or myocardial infarction in the TAXUS Liberte Post-Approval Study enrolled population. For pooled data from the TAXUS Liberté and TAXUS Express patient populations, please see the citations.

Secondary Outcome Measures :

1. Incremental Rate of Stent Thrombosis (Protocol Definition) [ Time Frame: 1-2 years ]

   Stent Thrombosis (protocol definition):

   The occurrence of any of the following:

   1. Clinical presentation of acute coronary syndrome with angiographic evidence of stent thrombosis:

      Angiographic documentation of acute complete occlusion (TIMI flow 0 or 1) of a previously successfully treated artery (TIMI flow 2 to 3 immediately after stent placement and diameter stenosis less than or equal to 30%) and/or Angiographic documentation of a flow limiting thrombus within or adjacent to a previously successfully treated lesion

   2. Acute MI in the distribution of the treated vessel.
   3. Death within the first 30 days post index procedure (without other obvious cause) is considered a surrogate for stent thrombosis when angiography is not available.
2. Target Vessel Failure (TVF) for the Medically-Treated Diabetic Population [ Time Frame: 12 months ]
   Target vessel failure (TVF) for TAXUS Libertē Post-Approval Study medically-treated diabetic population. For pooled data from the TAXUS Liberté population, please see the citations
3. Rate of Major Adverse Cardiac and Cerebrovascular Events (MACCE) [ Time Frame: 6 months ]
   • MACCE defined as the composite of cardiac death, myocardial infarction, target vessel revascularization and stroke.
   • Binary rate
4. Rate of Major Adverse Cardiac and Cerebrovascular Events (MACCE) [ Time Frame: 12 months ]
   • MACCE defined as the composite of cardiac death, myocardial infarction, target vessel revascularization and stroke.
   • Binary rate
5. Rate of Major Adverse Cardiac & Cerebrovascular Events (MACCE): Study Stent Related [ Time Frame: 6 months ]
   MACCE defined as the composite of cardiac death, myocardial infarction, target vessel revascularization and stroke.
6. Rate of Major Adverse Cardiac and Cerebrovascular Events (MACCE): Study Stent Related [ Time Frame: 12 months ]
   • MACCE defined as the composite of cardiac death, myocardial infarction, target vessel revascularization and stroke.
   • Binary rate
7. Rate of Major Adverse Cardiac Events (MACE) [ Time Frame: 6 months ]
   • MACE defined as the composite of cardiac death, myocardial infarction and target vessel revascularization.
   • Binary rate
8. Rate of Major Adverse Cardiac Events (MACE) [ Time Frame: 12 months ]
   • MACE defined as the composite of cardiac death, myocardial infarction and target vessel revascularization.
   • Binary rate
9. Rate of Major Adverse Cardiac Events (MACE): Study Stent Related [ Time Frame: 6 months ]
   • MACE defined as the composite of cardiac death, myocardial infarction and target vessel revascularization.
   • Binary rate
10. Rate of Major Adverse Cardiac Events (MACE): Study Stent Related [ Time Frame: 12 months ]
    • MACE defined as the composite of cardiac death, myocardial infarction and target vessel revascularization.
    • Binary rate
11. Rate of Target Vessel Failure (TVF) [ Time Frame: 6 months ]
    • Target vessel failure is defined as any revascularization of the target vessel, MI (Q- and non-Q wave) related to the target vessel, or death related to the target vessel.
    • Binary Rate
12. Rate of Target Vessel Failure (TVF) [ Time Frame: 12 months ]
    • Target vessel failure is defined as any revascularization of the target vessel, MI (Q- and non-Q wave) related to the target vessel, or death related to the target vessel.
    • Binary rate
13. Rate of Cardiac Death or Myocardial Infarction (MI) [ Time Frame: 6 months ]
    - Binary Rate
14. Rate of Cardiac Death or Myocardial Infarction (MI) [ Time Frame: 12 months ]
    - Binary Rate
15. Rate of All Cause Death [ Time Frame: 6 months ]
    -Binary rate
16. Rate of All Cause Death [ Time Frame: 12 months ]
    -Binary rate
17. Rate of Cardiac Death [ Time Frame: 6 months ]
    -Binary rate
18. Rate of Cardiac Death [ Time Frame: 12 months ]
    -Binary rate
19. Rate of Cardiac Death: Study Stent Related [ Time Frame: 6 months ]
    -Binary rate
20. Rate of Cardiac Death: Study Stent Related [ Time Frame: 12 months ]
    -Binary rate
21. Rate of Myocardial Infarction (MI) [ Time Frame: 6 months ]
    -Binary rate
22. Rate of Myocardial Infarction (MI) [ Time Frame: 12 months ]
    -Binary rate
23. Rate of Myocardial Infarction (MI): Study Stent Related [ Time Frame: 6 months ]
    -Binary rate
24. Rate of Myocardial Infarction (MI): Study Stent Related [ Time Frame: 12 months ]
    -Binary rate
25. Rate of Target Vessel Reintervention (TVR) [ Time Frame: 6 months ]
    -Binary rate
26. Rate of Target Vessel Reintervention (TVR) [ Time Frame: 12 months ]
    -Binary rate
27. Rate of Target Vessel Reintervention (TVR): Study Stent Related [ Time Frame: 6 months ]
    -Binary rate
28. Rate of Target Vessel Reintervention (TVR): Study Stent Related [ Time Frame: 12 months ]
    -Binary rate
29. Rate of Stroke [ Time Frame: 6 months ]
    -Binary Rate
30. Rate of Stroke [ Time Frame: 12 months ]
    -Binary Rate
31. Rate of Major Bleeding [ Time Frame: 6 months ]
    • Major Bleeding defined as the composite of severe or moderate bleeding complication (based upon GUSTO classification).
    • Binary rate
32. Rate of Major Bleeding [ Time Frame: 12 months ]
    • Major Bleeding defined as the composite of severe or moderate bleeding complication (based upon GUSTO classification).
    • Binary rate
33. Rate of Stent Thrombosis (ARC Definite + Probable) [ Time Frame: 6 months ]
    • ARC - Academic Research Consortium
    • Binary rate
34. Rate of Stent Thrombosis (ARC Definite + Probable) [ Time Frame: 12 months ]
    • ARC - Academic Research Consortium
    • Binary Rate
35. Rate of Stent Thrombosis (Protocol Definition) [ Time Frame: 6 months ]

    -Binary rate

    The occurrence of any of the following:

    1. Clinical presentation of acute coronary syndrome with angiographic evidence of stent thrombosis:

       Angiographic documentation of acute complete occlusion (TIMI flow 0 or 1) of a previously successfully treated artery (TIMI flow 2 to 3 immediately after stent placement and diameter stenosis less than or equal to 30%) and/or Angiographic documentation of a flow limiting thrombus within or adjacent to a previously successfully treated lesion

    2. Acute MI in the distribution of the treated vessel.
    3. Death within the first 30 days post index procedure (without other obvious cause) is considered a surrogate for stent thrombosis when angiography is not available.
36. Rate of Stent Thrombosis (Protocol Definition) [ Time Frame: 12 months ]

    -Binary rate

    The occurrence of any of the following:

    1. Clinical presentation of acute coronary syndrome with angiographic evidence of stent thrombosis:

       Angiographic documentation of acute complete occlusion (TIMI flow 0 or 1) of a previously successfully treated artery (TIMI flow 2 to 3 immediately after stent placement and diameter stenosis less than or equal to 30%) and/or Angiographic documentation of a flow limiting thrombus within or adjacent to a previously successfully treated lesion

    2. Acute MI in the distribution of the treated vessel.
    3. Death within the first 30 days post index procedure (without other obvious cause) is considered a surrogate for stent thrombosis when angiography is not available.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Non-Probability Sample

Study Population

All-comers study with follow-up through 3 years.

Criteria

Enrollment Inclusion Criteria

• Patient is > 18 years of age.
• Consecutive patients who have signed an Informed Consent Form, who do not otherwise meet applicable exclusion criteria, and who are eligible to receive a TAXUS Liberté Stent and the study required DAPT will be evaluated for enrollment in this study.

Enrollment Exclusion Criteria

• Patient with known hypersensitivity to paclitaxel or structurally related compounds.
• Patient with known hypersensitivity to the polymer or any of its individual components.
• Patient judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper placement of the stent or delivery device.
• Patient who cannot receive the protocol required dual antiplatelet therapy.
• Patient on warfarin or similar anticoagulant therapy.
• Patient with known pregnancy.
• Planned surgery necessitating discontinuation of antiplatelet therapy(> 14 days)within the 30-months following enrollment.
• Current medical condition with a life expectancy of less than 3 years.
• Patient currently enrolled in another device or drug study whose protocol specifically excludes concurrent enrollment or that involves blinded placement of a drug-eluting stent other than the TAXUS Liberté Stent.
• Patient judged unable to cooperate with prolonged DAPT.
• Patient unable to give informed consent.
• Patient judged inappropriate for randomization due to other condition requiring chronic thienopyridine use.
• Patient treated with both a drug-eluting stent and a bare-metal stent during the index procedure.
• Patient who experienced a prior transient ischemic attack (TIA) or a prior stroke.
• Patient requiring chronic daily use (greater than 2 consecutive weeks) of non-steroidal anti-inflammatory drugs (NSAIDs) with the exception of aspirin. Occasional use of NSAIDs on an as needed or "prn" schedule is not exclusionary.
• Patient with active pathological bleeding (such as peptic ulcer or intracranial hemorrhage).

Additional Exclusion Criteria (applicable only after patient enrollment has reached approximately 3600)

• Patient who experienced a myocardial infarction (MI) within 72 hours prior to the index procedure.
• Patient with a history of (includes current) left main coronary artery disease.
• Patient who requires stenting of > 1 vessel with a TAXUS Liberté stent during the index procedure.
• Patient who requires stenting of > 2 vessels during the index procedure.
• Patient who requires a staged procedure within 6-weeks following the index procedure, in whom > 1 vessel was stented during the index procedure.
• Patient with cardiogenic shock.
• Patient with acute or chronic renal dysfunction (serum creatinine >3.0 mg/dl or patient receiving dialysis).

• Target Lesion that meets any of the following criteria:

  • Located within a saphenous vein graft or an arterial graft
  • Chronic total occlusion
  • Restenosis from a previously implanted drug-eluting or bare-metal stent
  • Previous use of intravascular brachytherapy in target vessel
  • Lesion involves a bifurcation
  • Lesion is ostial in location
  • Severe tortuosity in the target lesion or target vessel proximal to the target lesion
  • Moderate or severe calcification by visual estimate in the target lesion or target vessel proximal to the target lesion
  • RVD < 2.5 mm or RVD > 3.75 mm
  • Lesion length > 28 mm

Randomization Inclusion Criteria (12-months):

• Patient is "12-Month Clear," which is defined as patients enrolled in the study who are free from all death, MI, stroke, repeat coronary revascularization, stent thrombosis and major bleeding (severe or moderate by GUSTO classification) 12 months after stent implantation and who are compliant with 12 months of DAPT following stent implantation. Exceptions to this rule are: Patients who experience repeat PCI, stent thrombosis and/or myocardial infarction occurring within 6 weeks after the index procedure will not be excluded from the definition of 12-Month Clear.
• Patient was compliant with DAPT during the first 12 months of the study. Compliance is defined as the patient taking between 80% and 120% of prasugrel in the 0-6 month and 6-12 month periods without an interruption of therapy longer than 14 days. Compliance at both time points is required to be considered 12-Month Clear.

Randomization Exclusion Criteria (12-months):

• Known pregnancy.
• Patient switched from prasugrel to other thienopyridine after discharge from index hospitalization.
• Patient switched maintenance dose of prasugrel (such as 10mg to 5mg; or 5mg to 10mg) within 6-months prior to randomization.
• Percutaneous coronary intervention or cardiac surgery between 6 weeks post index procedure and randomization.
• Planned surgery necessitating discontinuation of antiplatelet therapy (> 14 days) within the 21 months following randomization.
• Patients on warfarin or similar anticoagulant therapy.
• Current medical condition with life expectancy of less than 3 years.

Contacts and Locations

Locations

United States, Arizona

Advanced Cardiac Specialists

Mesa, Arizona, United States, 85206

United States, Arkansas

NEA Baptist Memorial Hospital

Jonesboro, Arkansas, United States, 72401

St. Bernard's Medical Center

Jonesboro, Arkansas, United States, 72401

Baptist Health Medical Center

Little Rock, Arkansas, United States, 72205

United States, California

Bakersfield Memorial Hospital

Bakersfield, California, United States, 93301

Bakersfield Heart

Bakersfield, California, United States, 93308

Mercy General Hospital

Sacramento, California, United States, 95819

Alvarado Hospital

San Diego, California, United States, 92120

Stanford University Medical Center

Stanford, California, United States, 94305

Torrance Memorial Medical Center

Torrance, California, United States, 90505

United States, Colorado

St. Anthony Central Hospital

Denver, Colorado, United States, 80204

Medical Center of the Rockies (Loveland)

Loveland, Colorado, United States, 80538

United States, Connecticut

St. Vincent's Medical Center

Bridgeport, Connecticut, United States, 06606

United States, Delaware

Christiana Hospital

Newark, Delaware, United States, 19718

United States, Florida

JFK Medical Center

Atlantis, Florida, United States, 33462

North Florida Regional Medical Center

Gainesville, Florida, United States, 32605

Baptist Medical Center

Jacksonville, Florida, United States, 32207

Memorial Hospital Jacksonville/ Orange Park Medical Center

Jacksonville, Florida, United States, 32216

Holmes Regional Medical Center

Melbourne, Florida, United States, 32901

Florida Hospital

Orlando, Florida, United States, 32803

Baptist Hospital

Pensacola, Florida, United States, 32501

Sacred Heart Hospital

Pensacola, Florida, United States, 32504

Bayfront Medical Center

St. Petersburg, Florida, United States, 33705

Martin Memorial Medical Center

Stuart, Florida, United States, 34995

University Community Hospital

Tampa, Florida, United States, 33613

United States, Hawaii

Kaiser Foundation Hospitals

Honolulu, Hawaii, United States, 96819

United States, Idaho

Kootenai Medical Center

Coeur d'Alene, Idaho, United States, 83814

United States, Illinois

MacNeal Hospital

Berwyn, Illinois, United States, 60402

Jesse Brown VA Medical Center

Chicago, Illinois, United States, 60612

United States, Indiana

IU Health North Medical Center

Carmel, Indiana, United States, 46032

Indiana Heart Hospital

Indianapolis, Indiana, United States, 46250

United States, Kentucky

King's Daughters Medical Center- Kentucky Heart Institute

Ashland, Kentucky, United States, 41101

St. Joseph Hospital

Lexington, Kentucky, United States, 40504

United States, Louisiana

Christus St. Frances Cabrini Hospital

Alexandria, Louisiana, United States, 71301

Cardiovascular Research, LLC

Shreveport, Louisiana, United States, 71105

United States, Maine

Eastern Maine Medical Center

Bangor, Maine, United States, 04401

Central Maine Medical Center

Lewiston, Maine, United States, 04240

United States, Michigan

Genesys Regional Medical Center

Grand Blanc, Michigan, United States, 48439

Ingham Regional Medical Center

Lansing, Michigan, United States, 48910

Mid Michigan Medical Center

Midland, Michigan, United States, 48670

St. Mary's Medical Center

Mt. Pleasant, Michigan, United States, 48858

Northern Michigan Hospital

Petoskey, Michigan, United States, 49770

Covenant Medical Center

Saginaw, Michigan, United States, 48602

Providence Hospital

Southfield, Michigan, United States, 48075

Lakeland Hospital at St. Joseph

St. Joseph, Michigan, United States, 49085

United States, Minnesota

North Memorial Medical Center

Minneapolis, Minnesota, United States, 55422

United Heart and Vascular Clinic

St. Paul, Minnesota, United States, 55102

United States, Mississippi

Memorial Hospital at Gulfport

Gulfport, Mississippi, United States, 39501

North Mississippi Medical Center

Tupelo, Mississippi, United States, 38801

United States, Missouri

Freeman West Hospital

Joplin, Missouri, United States, 64804

Cox Medical Centers

Springfield, Missouri, United States, 65807

St. John's Mercy Medical Center

St. Louis, Missouri, United States, 63141

United States, New Jersey

Our Lady of Lourdes Medical Center

Camden, New Jersey, United States, 08035

Hackensack University Medical Center

Hackensack, New Jersey, United States, 07601

Jersey Shore University Medical Center

Neptune, New Jersey, United States, 07753

United States, New Mexico

Heart Hospital of New Mexico

Albuquerque, New Mexico, United States, 87102

United States, New York

Maimonides Medical Center

Brooklyn, New York, United States, 11219

Lenox Hill Hospital

New York, New York, United States, 10021

Columbia University/ New York Presbyterian Hospital

New York, New York, United States, 10032

St. Elizabeth Medical Center

Utica, New York, United States, 13501

United States, North Carolina

Gaston Memorial Hospital

Gastonia, North Carolina, United States, 28054

Wake Medical Center

Raleigh, North Carolina, United States, 27610

United States, Ohio

Ohio State University Medical Center

Columbus, Ohio, United States, 43210

Med Central Health System- Mid Ohio Heart Clinic

Mansfield, Ohio, United States, 44906

St. Vincent Mercy Medical Center

Toledo, Ohio, United States, 43608

United States, Oklahoma

University of Oklahoma Health Science Center

Oklahoma City, Oklahoma, United States, 73104

Oklahoma Heart Hospital

Oklahoma City, Oklahoma, United States, 73120

United States, Pennsylvania

Conemaugh Valley Memorial Hospital

Johnstown, Pennsylvania, United States, 15905

Presbyterian University of Pennsylvania Medical Center

Philadelphia, Pennsylvania, United States, 19104

United States, South Carolina

Palmetto Richland Memorial Hospital

Columbia, South Carolina, United States, 29203

Sisters of Charity Providence Hospital

Columbia, South Carolina, United States, 29204

Grand Strand Regional Medical Center

Myrtle Beach, South Carolina, United States, 29572

United States, South Dakota

Rapid City Regional Hospital

Rapid City, South Dakota, United States, 57701

Avera Heart Hospital of South Dakota

Sioux Falls, South Dakota, United States, 57108

United States, Tennessee

Jackson Madison County General Hospital

Jackson, Tennessee, United States, 38305

United States, Texas

Baylor Jack and Jane Hamilton Heart and Vascular Hospital

Dallas, Texas, United States, 75226

Doctors Hospital at Renaissance/ McAllen Heart Hospital

Edinburg, Texas, United States, 78539

Michael E. DeBakey VA Medical Center

Houston, Texas, United States, 77030

Kingwood Medical Center

Kingwood, Texas, United States, 77339

Methodist Texsan Hospital

San Antonio, Texas, United States, 78201

Cardiovascular Associates of East Texas Medical Center

Tyler, Texas, United States, 75701

United States, Wisconsin

Meriter Hospital, Inc.

Madison, Wisconsin, United States, 53715

Sponsors and Collaborators

Boston Scientific Corporation

Eli Lilly and Company

Daiichi Sankyo, Inc.

Investigators

• Principal Investigator: David P Lee, MD; Stanford University
• Principal Investigator: Kirk N Garratt, MD; Lenox Hill Hospital
• Study Director: Peter M Maurer, MPH; Boston Scientific Corporation

More Information

Publications of Results:

Lee DP, Paulus R, Giri K, Carr J, Baran KW, Hassel D, Winters KJ, Christen T, Dawkins KD, Garratt KN. TCT-167 Primary endpoint results of the TAXUS Libertē post-approval study. Journal of the American College of Cardiology. 2013;62:B54-B54

Garratt, KN, Lambert C, Kabour A, Stewart M, Hall P, Phillips WJ, Winters KJ, Christen T, Dawkins KD, Lee DP TCT-148 TAXUS Liberté PES With ASA + Prasugrel Is Associated With Low TVF, Bleeding And Adverse Event Rates Among Diabetic Patients With "On-Label" Stent Indications. Journal of the American College of Cardiology, 2013; 62 (18_S1): B47-B47.

Other Publications:

Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, Bulle TM. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation. 1990 Oct;82(4):1193-202.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Garratt KN, Weaver WD, Jenkins RG, Pow TK, Mauri L, Kereiakes DJ, Winters KJ, Christen T, Allocco DJ, Lee DP. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement. Circulation. 2015 Jan 6;131(1):62-73. doi: 10.1161/CIRCULATIONAHA.114.013570. Epub 2014 Nov 16.

• Responsible Party: Boston Scientific Corporation
• ClinicalTrials.gov Identifier: NCT00997503
• Other Study ID Numbers: H7T-MC-TADN; S2035 ( Other Identifier: Boston Scientific )
• First Posted: October 19, 2009
• Results First Posted: April 13, 2015
• Last Update Posted: August 7, 2015
• Last Verified: March 2015

Additional relevant MeSH terms:

Coronary Artery Disease; Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Aspirin; Paclitaxel; Prasugrel Hydrochloride; Antineoplastic Agents, Phytogenic; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Molecular Mechanisms of Pharmacological Action; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Analgesics; Sensory System Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Anti-Inflammatory Agents; Antirheumatic Agents; Fibrinolytic Agents; Fibrin Modulating Agents; Platelet Aggregation Inhibitors; Cyclooxygenase Inhibitors; Enzyme Inhibitors